We target Auto-Immune Diseases

Ermium Therapeutics is developing orally available drug candidates allowing the efficient control of type 1 interferons.

These drug candidates have the potential to address a wide range of chronic auto-immune diseases, affecting millions of people worldwide and include type I interferon-mediated diseases.

In response to an unknown trigger, the immune system may attack the body’s own tissues weakening . Treatment for autoimmune diseases generally focuses on reducing immune system activity.

Severity Of Auto-Immune Diseases​​

1. Widespread

There are more than 80 autoimmune diseases. While some are well known and include for instance Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel diseases, Multiple sclerosis and type 1 diabetes mellitus, other are rare and difficult to diagnose.

The world prevalence of auto-immune diseases is increasing and they affect up to 10% of the population in Europe and North America.

2. Incurable

Most of these diseases have no cure and the most serious conditions require lifelong treatment to ease symptoms.

3. Medication

The drugs to treat autoimmune diseases target different components of the immune system. They can be : 
  • general immunosuppressants such as steroids, colchicine, methotrexate, 
  • biologics that have to be injected are targeting specific component of the immune system (TNFalpha, IL-1beta, IL-6, CD20, B cell growth factor, etc.)
  • JAK inhibitors which are small molecules which help immune cells to lower the release inflammatory signals.

Legal notices

Ermium Therapeutics registered under number SIRET 85199803900016, is a simplified stock company.

Located at 16 Boulevard Saint Germain 75005 PARIS and with a registered capital of €1,352, it specializes in research and development in biotechnology (7211Z).

Intellectual property :

This site constitutes a work protected by copyright in force in France. In addition, unless otherwise stated, the intellectual property rights in the documents contained in the site (texts, photographs, images, etc.) and each of the elements created for this site are the exclusive property of Ermium Therapeutics. Reproduction of all elements published on the site Ermium.com is expressly prohibited (article 122.4 of the code of the intellectual property).

Sites linked directly or indirectly to the Ermium.com site are not under its control. Consequently, Ermium Therapeutics assumes no responsibility for the information published on these sites.

Hosting

OVH:
SAS with capital of €10,069,020
RCS Lille Métropole 424,761,419,00045
APE Code 2620Z
VAT number: FR 22 424 761 419
Headquarters: 2 rue Kellermann – 59100 Roubaix – France

Publication Director :
Joel Crouzet

contact@ermium.com

Stages de couture

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Ateliers du dimanche

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Cours enfant

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours réalisation 

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours coupe

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Préparation au C.A.P.

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.